Clinical trials
Hematology clinical trials
Below are recruiting hematology clinical trials, each written for real people, not researchers. We’re tracking 603 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06765876RecruitingEarly Phase 1
CAR T-cell therapy for CD123+ blood cancers
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called CD123 on cancer cells. It is for people with certain blood cancers (AML, MDS-IB2, BPDCN, or ALL) that have come back or not responded to other treatments.
PragueAges 18–70 - NCT06795815Recruiting
Using the Go Wish Game for Future Care Planning
This trial tests a game called 'Go Wish' that helps people with serious cancer think about and talk about their future care wishes. It's designed to help you plan ahead with your care team.
Reggio EmiliaAges 18–99 - NCT06807606RecruitingPhase 2
Cord blood transplant after relapse from first transplant
This trial tests a second transplant using two donated umbilical cord blood units for people whose blood cancer returned after a first stem cell transplant. It aims to offer a potential cure for high-risk blood cancers.
Houston, TexasAges Up to 60 years - NCT06834412Recruiting
New PET scan for blood cancer staging
This study tests a new type of PET scan called 68Ga-Pentixafor to see how well it finds and stages blood cancers (like non-Hodgkin lymphoma and myeloma). It will compare this new scan to the standard FDG-PET scan. If you join, you may get more accurate information about your cancer.
Xi'an, ShaanxiAges 18–75 - NCT06851702Recruiting
Tracking hormone side effects from immunotherapy in blood cancer
This study looks at people with certain types of blood cancer (lymphoma or leukemia) who are getting immunotherapy drugs called checkpoint inhibitors. Researchers want to learn how these drugs affect the body's hormone system, so doctors can better manage these side effects.
Bologna, BolognaAges 18 years+ - NCT07019038Recruiting
Autoimmune hemolytic anemia long-term study
This study looks at people with autoimmune hemolytic anemia (AIHA) over time. It aims to understand the disease better and find ways to improve care.
Tianjin, Tianjin MunicipalityAges Any age - NCT07019766Recruiting
Long-term study of LGLL leukemia patients
This study follows people with large granular lymphocytic leukemia (LGLL) over time to learn more about the disease. It collects information from patients treated at the Institute of Hematology and Blood Diseases Hospital in China.
Tianjin, Tianjin MunicipalityAges Any age - NCT07035938Recruiting
T-Cell Health in Blood Cancer Patients Study
This study looks at how T-cells (a type of immune cell) work in people with certain blood cancers (B-cell lymphoma or multiple myeloma) compared to healthy volunteers. The goal is to learn more about the immune system in these cancers, which may help improve future treatments.
Xiamen, FujianAges 18 years+ - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07052370RecruitingPhase 1
New stem cell transplant for children with high-risk blood cancer
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07085065Recruiting
Virtual reality for pain and anxiety during blood cancer procedures
This trial tests whether watching a virtual reality experience during a medical procedure can help reduce pain and anxiety for people with blood cancers. You may be able to take part if you are getting a bone marrow biopsy, spinal tap, blood draw, or chemotherapy.
Tunis, Sfax GovernorateAges 6 years+ - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07122674Recruiting
New PET scan for blood cancers
This study tests a new PET scan method (using a special tracer called 18F-Pentixafor) to see if it can better find and track blood cancers. It may help your doctors get more detailed images with less radiation.
Hangzhou, ZhejiangAges 18–80 - NCT07131254RecruitingEarly Phase 1
Study of GT719 cell therapy for CD19-positive leukemia or lymphoma
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
Ganzhou, JiangxiAges 18–75 - NCT07135778Recruiting
Combination antifungal therapy for fungal infections in blood cancer
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07162038RecruitingPhase 1
Combining CAR-T cells with a stem cell transplant for blood cancers
This trial tests adding anti-CD19 CAR-T cells to a half-matched stem cell transplant for people with high-risk blood cancers. The goal is to see if this combination is safe and can improve outcomes.
Bethesda, MarylandAges 18–75 - NCT07173166Recruiting
Managing side effects after CAR-T treatment
This study tests if non-drug approaches like lifestyle changes or supportive care can reduce nerve-related side effects in people with blood cancers who are receiving CAR-T therapy. It aims to help patients feel better during treatment.
Valencia, ValenciaAges 18–80 - NCT07173595RecruitingPhase 1
QLS2309 for CD70-positive blood cancers that returned
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07189117Recruiting
Study of cell metabolism in blood cancers
This study looks at how blood cancer cells use energy (metabolism) and how that affects the immune system. Researchers hope to find new ways to treat these cancers by understanding cell metabolism better.
BaselAges 18 years+ - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Duarte, CaliforniaAges 18 years+ - NCT00001620Enrolling by invitation
NIH screening to see which blood studies fit you
This study is a general screening step at the NIH Clinical Center to check whether you might qualify for other NHLBI research protocols. It helps match you (or a donor/healthy volunteer) to the right study and confirms you can consent to participate.
Bethesda, MarylandAges 2–100
Hear when a new Hematology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematology?
- Yes. Clin2 currently lists 603 recruiting hematology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.